Sarah Rodriguez to Angiogenesis Inhibitors
This is a "connection" page, showing publications Sarah Rodriguez has written about Angiogenesis Inhibitors.
Connection Strength
2.321
-
Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. Ophthalmic Surg Lasers Imaging Retina. 2020 09 01; 51(9):486-493.
Score: 0.629
-
Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):337-343.
Score: 0.576
-
Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. J AAPOS. 2019 04; 23(2):88.e1-88.e6.
Score: 0.565
-
Association of Health Insurance Status With Severity and Treatment Among Infants With Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus. 2023 Nov-Dec; 60(6):e75-e78.
Score: 0.196
-
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2021 09; 41(9):2377-2378.
Score: 0.166
-
Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. J AAPOS. 2020 06; 24(3):149.e1-149.e5.
Score: 0.154
-
Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018 11 01; 49(11):893-896.
Score: 0.035